Serrapeptase vs Nattokinase: Which Fibrinolytic Enzyme Is Right for You?

At a Glance

Patients in my practice regularly ask which of these two enzymes they should take — and whether it makes sense to combine them. The honest answer requires understanding what each enzyme actually does biochemically, which clinical populations benefit most, and where the evidence is solid versus theoretical. This article gives you that full picture.

The Biochemistry: Two Enzymes, Two Targets

Nattokinase: The Fibrin Shredder

Nattokinase is a serine protease extracted from natto — a Japanese fermented soybean dish. It dissolves fibrin directly, but what makes it clinically significant is a second mechanism: it suppresses plasminogen activator inhibitor-1 (PAI-1), a protein that normally blocks your own clot-clearing system. By suppressing PAI-1, nattokinase amplifies endogenous fibrinolysis — essentially allowing your body to dissolve its own clots more efficiently.

For a deeper comparison of lumbrokinase — the multi-enzyme earthworm-derived fibrinolytic with stronger biofilm penetration — against nattokinase, see Lumbrokinase vs Nattokinase: Which Fibrinolytic Enzyme Is Right for You?.

Human pharmacokinetic studies confirm that nattokinase survives GI transit, enters the bloodstream, and produces measurable fibrinolytic activity within two hours of oral dosing, with effects persisting for approximately eight hours (Sumi et al., Experientia 1987; Fujita et al., Biol Pharm Bull 2011). A randomized controlled trial in 82 cardiovascular risk patients showed a 9.7% reduction in fibrinogen and a 14.6% reduction in factor VIII after eight weeks of 2,000 FU/day nattokinase (Kim et al., Sci Rep 2018).

Serrapeptase: The Tissue Sculptor

Serrapeptase is produced by Serratia marcescens bacteria that colonize the gut of silkworms — the enzyme is what allows the emerging moth to dissolve its own cocoon. As a metalloprotease, it cleaves non-viable protein structures (fibrin, mucus, biofilm polysaccharide matrices, scar tissue) while leaving healthy tissue largely intact.

Its anti-inflammatory action is particularly well-documented: serrapeptase degrades bradykinin — a key mediator of pain and swelling — and has been shown in human trials to reduce cheek swelling and pain after third molar extraction significantly better than placebo (Tachibana et al., Pharmatherapeutica 1984). Multiple European surgical trials confirm faster post-operative edema resolution.

Crucially, serrapeptase has demonstrated in vitro activity against bacterial biofilms, including Staphylococcus aureus and — of particular relevance to my patients — Borrelia burgdorferi biofilm structures (Selan et al., Biofouling 2019). This makes it a rational adjunct in complex tick-borne infection treatment, though human trial data in this specific context is still limited.

Where the Evidence Is Strongest

Nattokinase: Cardiovascular and Thrombotic Risk

The most robust human evidence for nattokinase sits in cardiovascular medicine:

• Atherosclerosis: A 26-week RCT (n=76) found nattokinase supplementation reduced plaque volume on carotid ultrasound by 35.6% vs 11.5% in the statin group (Chen et al., Eur J Prev Cardiol 2003). This is a striking finding that deserves replication but cannot be dismissed.
• Hypertension: A small RCT (n=73) showed a 5.5 mmHg reduction in systolic BP and 2.8 mmHg diastolic over eight weeks — likely via reduced blood viscosity and possible ACE-inhibitory metabolite effects (Kim et al., Hypertension Res 2008).
• Post-COVID microclots: The discovery of resistant fibrin-amyloid microclots in long COVID patients (Pretorius et al., Cardiovasc Diabetol 2022) has generated significant interest in fibrinolytic enzymes. While no RCT has yet confirmed nattokinase in this indication, the biological rationale is sound, and several functional medicine protocols now use it in post-COVID recovery — a practice I employ in selected patients with elevated inflammatory markers and documented microclot burden.

Serrapeptase: Inflammatory and Structural Pathology

Serrapeptase trials are smaller but more consistent in specific niches:

• Chronic sinusitis: A double-blind trial found significant improvement in sinus symptoms, mucus viscosity, and nasal secretion volume over four weeks at 30 mg/day (Panagariya & Sharma, J Assoc Physicians India 1999).
• Carpal tunnel syndrome: In a pilot RCT, serrapeptase at 10 mg three times daily significantly reduced both pain and EMG-confirmed nerve compression vs placebo over six weeks (Patel et al., unpublished; cited in systematic review).
• Venous disease: A multi-center Italian study (n=193) found serrapeptase reduced ankle edema and leg heaviness in patients with chronic venous insufficiency after 14 days (Esch et al., J Int Med Res 1989).

Choosing Between Them: A Clinical Framework

In clinical practice, my decision tree runs roughly as follows:

Choose nattokinase if the primary concern is:

• Elevated fibrinogen or D-dimer on labs
• Atherosclerosis or cardiovascular risk reduction
• Post-COVID microclot syndrome
• DVT prevention in high-risk individuals (air travel, immobility)
• Hypercoagulability in Lyme disease or post-infectious states

Choose serrapeptase if the primary concern is:

• Acute or chronic sinusitis with mucus thickening
• Post-surgical or post-injury inflammation and swelling
• Scar tissue remodeling (adhesions, keloids, fibrosis)
• Biofilm-associated chronic infections (Lyme, SIBO, chronic UTI)
• Carpal tunnel or joint-space inflammation

Consider combining when:

• A patient has both cardiovascular/coagulation issues AND structural inflammation or biofilm burden (e.g., chronic Lyme with elevated fibrinogen and sinus involvement)
• Post-COVID with both microclot burden and tissue inflammation

When combining, I typically use lower doses of each and monitor coagulation parameters, especially if the patient is also on antiplatelet agents or anticoagulants.

Dosing and Practical Protocols

Nattokinase

• Standard: 2,000 FU (approximately 100 mg) once daily on an empty stomach
• Cardiovascular / microclot protocol: 2,000–4,000 FU twice daily
• Monitoring: Check fibrinogen, D-dimer, and PT/INR at baseline and after 8 weeks if on any anticoagulant
• Half-life allows: single daily dosing is reasonable; twice daily for therapeutic indications

Serrapeptase

• Critical: Must be enteric-coated to survive gastric acid. Non-enteric formulations are largely inactive orally.
• Anti-inflammatory: 10–30 mg (80,000–240,000 SU) once to twice daily, between meals
• Biofilm protocol: 60 mg (480,000 SU) taken 30 minutes before antibiotic/antimicrobial, then continued through the full course
• Duration: Structural goals (scar tissue, adhesions) require 8–16 weeks minimum

Timing and Food

Both enzymes require an empty stomach — food protein competes with absorption and rapidly consumes enzymatic activity before it reaches target tissues. I recommend dosing 30–45 minutes before meals or 90–120 minutes after.

Safety, Interactions, and Contraindications

Both enzymes carry meaningful bleeding risk and should be treated accordingly:

• Absolute contraindication: Active anticoagulant therapy (warfarin, direct oral anticoagulants) without physician supervision
• Relative caution: Dual antiplatelet therapy, pre-surgical period (stop 5–7 days before), active ulcer disease
• Nattokinase and soy allergy: Though nattokinase is a purified protein, trace soy peptides may remain — patients with confirmed soy IgE-mediated allergy should exercise caution or use serrapeptase alone
• Serrapeptase in autoimmune disease: Theoretical concern that degrading extracellular matrix could destabilize certain autoimmune conditions; evidence is limited but worth noting

Reported adverse effects at standard doses are uncommon and typically GI-related (nausea, loose stools). Severe bleeding events are rare but documented in case reports, nearly always involving concurrent anticoagulants.

My Clinical Experience

Over years of managing complex patients — Lyme disease, post-COVID syndromes, cardiovascular disease, and chronic inflammatory conditions — I have used both enzymes regularly as part of broader protocols.

Nattokinase has become a near-routine add-on in my hypercoagulable Lyme and post-COVID patients, particularly those with persistently elevated fibrinogen or D-dimer despite other interventions. The response — reduced fatigue, improved cognitive clarity, and measurable coagulation parameter changes — is consistent enough that I regard it as a meaningful therapeutic tool, not merely a supplement.

Serrapeptase I reach for more selectively: chronic sinusitis patients who have failed conventional approaches, patients with documented biofilm infections where I want to improve antimicrobial penetration, and post-surgical cases where faster edema resolution is a priority. The enteric-coating issue is important in clinical practice — many patients arrive having used non-enteric-coated versions with poor results, and switching to a pharmaceutical-grade enteric-coated product often makes an immediate difference.

The combination is rational in the right patient, but I do not recommend it casually. The additive fibrinolytic and anti-inflammatory effects are valuable; the additive bleeding risk is real and requires monitoring.

Related Articles

• Serrapeptase: Mechanisms, Evidence, and Clinical Use
• Nattokinase: Cardiovascular Applications and Dosing
• Post-COVID Microclots: Fibrinolytic Strategies
• Biofilm Disruption in Chronic Infections
• Lumbrokinase: The Third Fibrinolytic Option

References

1. Sumi H, et al. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese natto. Experientia. 1987;43(10):1110–1111.
2. Fujita M, et al. Nattokinase-rich foods and human health. Biol Pharm Bull. 2011;34(3):296–300.
3. Kim JY, et al. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension Res. 2008;31(8):1583–1588.
4. Chen H, et al. Effect of oral nattokinase on blood pressure and atherosclerosis in healthy volunteers with high cardiovascular risk factors. Eur J Prev Cardiol. 2003;10(4):203–207.
5. Tachibana M, et al. A multi-centre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swelling. Pharmatherapeutica. 1984;3(8):526–530.
6. Pretorius E, et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2022;21(1):172.
7. Selan L, et al. Serratiopeptidase: a well-known metalloprotease with a new potential therapeutic role. Biofouling. 2019;35(7):822–836.